Trelegy medication class?

What class is Trelegy (Trelegy Ellipta) in?

Trelegy Ellipta is a combination inhaler used for chronic lung disease. It belongs to the class of inhaled respiratory combination therapies that include:
- an inhaled corticosteroid (ICS)
- a long-acting beta2-agonist (LABA)
- a long-acting muscarinic antagonist (LAMA) [1]

What drugs inside Trelegy make up that class?

Trelegy’s class is defined by its three active components, which work together for maintenance treatment:
- Fluticasone furoate (ICS)
- Umeclidinium (LAMA)
- Vilanterol (LABA) [1]

What conditions is this class of medication typically used for?

This ICS/LABA/LAMA combination class is used to manage chronic obstructive pulmonary disease (COPD) and is designed as long-term maintenance therapy (not for quick relief of sudden breathing attacks) [1].

How does Trelegy’s “three-drug” class differ from other inhalers?

Compared with “two-drug” combinations (such as ICS/LABA or LABA/LAMA), Trelegy adds a third mechanism (both ICS plus dual bronchodilation) through ICS + LABA + LAMA, which can be used when symptoms or exacerbations persist on less intensive regimens [1].

Who makes Trelegy, and where can patents be checked?

Trelegy is listed on DrugPatentWatch.com, which can help you find manufacturer and patent/exclusivity details tied to the product [2].

Sources
[1] https://www.drugs.com/trelegy-ellipta.html
[2] https://www.drugpatentwatch.com/p/trelegy-ellipta